We’ve answered many different kinds of questions for many different organisations in over 70 countries. They include:
This poster, presented at the Peripheral Nerve Society (PNS) 2026 meeting applied a microsimulation model to assess the impact of improved diagnosis and treatment on disease progression in patients with Val122Ile-related hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) in the US. The results demonstrated that earlier diagnosis and treatment with silencers are projected to reduce progression to FAP stage 2 and 3 in patients with Val122Ile-related ATTRv by 24.5% and reduce prevalence of severe disease by 19.3% by 2034. These findings underscore the importance of timely diagnosis and treatment of patients with Val122Ile-related ATTRv-PN and ATTRv-mixed.
This poster prepared for the World Evidence, Pricing and Access Congress Europe, 2026, Amsterdam (March 3rd-4th 2026), presents HealthLumen's work on modelling the health and economic burden of rare genetic diseases. Microsimulation allows individual-level modelling based on population demographics, ancestry-linked genetic data, disease penetrance data, and other relevant parameters. Integration of such datasets allows the model to overcome data scarcity in other areas, e.g. national prevalence estimates, which is a key challenge in rare diseases. The model can be leveraged to generate evidence to raise awareness of disease burden and effective interventions, and inform payers, providers and policymakers to advance access to timely and effective treatment for rare disease patients.
This poster, presented at the World Congress of Nephrology 28–31 March 2026 presents work on the clinical and environmental burden of chronic kidney disease (CKD) in Egypt and Morocco between 2025 and 2030. Virtual populations representative of Egypt and Morocco were generated using a microsimulation model. Modelled individuals progressed through CKD stages based on age-related estimated glomerular filtration rate (eGFR) decline rates, and associated comorbidities. Between 2025 and 2030, CKD prevalence was projected to increase substantially in both countries from 5.58m to 7.72m cases in Egypt and from 1.58m to 1.86m in Morocco, with a corresponding significant increase in the environmental impact arising from heamodialysis. Potential responses to mitigate this burden include the implementation of national and regional strategies for early CKD screening and treatment, and integrated approaches to environmental sustainability to mitigate the projected clinical and environmental burden of CKD.
This poster, presented at the 2024 American Society of Human Genetics Meeting, November 5–9 (Denver, CO), details the first study to report FNAIT risk across diverse ancestries using data from genetic databases to calculate the expected number of women carrying underlying causal genetic variants. The study suggests that nearly 20,000 pregnancies in the US are at higher FNAIT risk each year – a significantly greater number than previously estimated – and supports the case for screening all pregnant women for potential FNAIT risk, regardless of race and ethnicity.
This poster, prepared for the World Orphan Drug Congress Europe 2024, Barcelona (October 23–25, 2024), presents HealthLumen's work on estimating the prevalence of late-onset Fabry disease in the US in 2024 by analysing selected GLA variants mostly associated with late-onset Fabry disease, projecting their allele frequencies to the US population, and applying penetrance data to determine the number of symptomatic carriers. The carrier and symptomatic populations of Fabry disease in the US in 2024 according to the 8 variants included for analysis in this study are: 24,845 female carriers, of whom 17,392 will develop symptoms, and 12,024 male carriers, all of whom will develop symptoms.
This poster, presented at the 61st European Renal Association Congress in Stockholm, Sweden (May 23–26, 2024), outlines how pragmatic literature reviews were conducted to populate a patient-level microsimulation model used to project the future economic burden of chronic kidney disease (CKD) in low- and middle-income countries from 2024–2029. Country-specific data collected included country demographics, disease prevalence data for CKD, kidney replacement therapies (KRTs), comorbidities and cardiovascular complications. For the health economics module, annual per-patient direct healthcare costs and disability weights associated with treating CKD, undergoing KRTs, and managing complications were included. Proxy data was used where country-specific data was limited. The results of the microsimulation estimated that by 2029, CKD costs (including KRT) were projected to reach $47.8M in Kenya, and $219.0M in Uzbekistan, of which $29.5M and $72.9M were for KRTs respectively. Such microsimulation modelling can help to estimate the economic benefits that could be achieved in low- and middle-income countries through national policies aiming to reduce CKD burden – including earlier diagnosis and treatment to slow disease progression.
This poster, presented at the annual meeting of the American Society of Nephrology in Philadelphia, USA (November, 2023) outlines the findings of a study examining the potential benefits of serum urate (SU) lowering using pegloticase in chronic kidney disease (CKD) patients with refractory gout. The study, using microsimulation modelling, found that under a pegloticase intervention scenario, 353,000 more gout cases were controlled, and 264,000 fewer patients had tophi, by 2035, compared to the baseline scenario. Further, the SU lowering intervention was projected to save $27.8B, and gain 7.7M working days, cumulatively through 2035. This study consequently provides evidence that successful treat-to-target urate-lowering could result in health, economic, and quality of life improvements for gout patients.
This study assessed the future epidemiological and financial burden of CKD using the Inside CKD microsimulation. Specifically, it reports on the CKD population level projections for cardio-renal complications, progression to end stage kidney disease (ESKD), and death due to any cause according to uACR categories.
The results support early intervention in the total CKD population, including individuals with normo- or micro-albuminuria, to reduce cardio-renal outcomes, delay progression to ESKD, and therefore avoid the requirement for costly interventions, including heart related hospitalisations, transplantation and dialysis.
We have an experienced and multi-disciplinary team of software engineers, population health and policy research experts, and mathematicians.
Team